Page 221 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Moderate-severe
Groups similar at baseline: Yes

Health Outcome Measures:

memantine placebo 75.5 75.5 67 63 92.5 90.1 10.2 9.9 129 weeks 126 weeks 9.49 9.25 Primary Outcome Measures: SIB; ADCS-ADL Secondary Outcome Measures: CIBIC-plus; NPI; BGP Timing of assessments: Baseline, and weeks 4, 8, 12, 18 and 24 Statistically significant benefit of MEM compared to placebo on ADCS-ADL (P = 0.03), NPI (P = 0.01), and BGP (P = 0.001) Intermediate Outcome Measures: Statistically significant benefit of MEM compared to placebo on SIB (P < 0.001), and CIBIC-plus (55% of MEM improved compared to 45% of placebo improved (

• •

Final Report Update 1 Authors: Tariot et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Baseline MMSE • Duration of DON treatment • DON dose (mg) • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs